Geron Corporation is a clinical biopharmaceutical company headquartered in Foster City, California, specializing in the development and commercialization of innovative therapies for myeloid hematologic neoplasms, particularly acalabrutinib and telomerase inhibitors. With a robust pipeline and a commitment to addressing unmet medical needs in this field, Geron aims to transform the treatment landscape for patients with blood cancers. The company is positioned at the forefront of hematology research, leveraging advanced scientific capabilities to deliver novel therapies with the potential for significant clinical impact.